Curis to Present at the Noble Financial Small Cap Equity Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 16, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that the Company will be presenting at the Noble Financial Equity Two Double------Seven Conference, being held August 20-21, 2007, at the Charleston Place Hotel in Charleston, South Carolina.
Curis' presentation will take place on Monday, August 20, 2007 at 9:00 AM EDT. Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of the company's business and collaborations. Mr. Passeri will also participate in a question and answer session following the presentation and one-on-one meetings throughout the day.
The presentation with streaming video and PowerPoint presentation will be webcast live at http://hosted.mediasite.com/hosted4/Viewer/?peid=f8e95499-49b 4-4790-8e32-6e189480f93c and archived on the websites of Curis at www.curis.com, and Noble Financial's conference website at www.two-007.net. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.
About Curis, Inc.
Curis, Inc. is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, Curis is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit Curis' website at www.curis.com.
Editor's Note: Due to the length of some of the URLs in this press release, it may be necessary to copy and paste them into your Internet browser's URL address field.
CONTACT: Curis, Inc. Michael P. Gray, 617-503-6632 CFO & COO email@example.com SOURCE: Curis, Inc.